A ONCE-WEEKLY GLP-1 RA
A ONCE-WEEKLY GLP-1 RA
A ONCE-WEEKLY GLP-1 RA
Ozempic® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.2
Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:
Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1
Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST
Main number:
905-629-4222
Toll-free:
1-800-465-4334
Main fax number:
905-629-8662
Toll-free fax number:
1-844-465-2225
